Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Table S5a. Odds ratio for DCB of clinical variables via univariate and multivariate logistics analysis

Variable	Univariate		Multivariate	
	OR (95% CI)	*P*	OR (95% CI)	*P*
Tumor histologic type	0.887 (0.468-1.683)	0.714	-	-
Age (year)	1.000 (0.973-1.028)	0.981	-	-
Gender	0.334 (0.153-0.728)	**0.006**	0.622 (0.240-1.613)	0.329
Smoking status	2.445 (1.408-4.247)	**0.002**	1.769 (0.885-3.538)	0.106
BMI	1.034 (0.945-1.132)	0.464	-	-
Clinical stage	0.524 (0.344-0.800)	**0.003**	0.638 (0.394-1.033)	0.068
EGFR mutation	0.777 (0.329-1.836)	0.565	-	-
Monotherapy	1.220 (0.625-2.382)	0.56	-	-
LOT	0.359 (0.196-0.658)	**0.001**	0.559 (0.265-1.181)	0.127
CEA	1.000 (0.998-1.001)	0.523	-	-
NSE	0.986 (0.964-1.009)	0.239	-	-
Hb	1.007 (0.995-1.019)	0.265	-	-
NLR-pre	0.977 (0.932-1.025)	0.346	-	-
NLR-post	0.831 (0.749-0.922)	**< 0.001**	0.846 (0.761-0.940)	0.002

BMI=body mass index. EGFR=epidermal growth factor receptor. LOT=line of therapy.

CEA=carcinoembryonic antigen. NSE=neuron specific enolase. Hb=hemoglobin.

NLR=neutrophil-lymphocyte Ratio.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Table S5b. Odds ratio for DCB of clinical variables via multivariate logistics analysis in each cohort of advanced NSCLC

Variable	D1		D2		D3	
	HR (95% CI)	*P*	HR (95% CI)	*P*	HR (95% CI)	*P*
Gender	0.622 (0.240-1.613)	0.329	0.956 (0.088-10.393)	0.970	0.541 (0.065-4.501)	0.570
Smoking status	1.769 (0.885-3.538)	0.106	1.795 (0.391-8.234)	0.452	0.681 (0.100-4.637)	0.695
Clinical stage	0.638 (0.394-1.033)	0.068	1.103 (0.414-2.938)	0.845	0.415 (0.180-0.959)	0.039
LOT	0.559 (0.265-1.181)	0.127	0.457 (0.077-2.727)	0.391	0.559 (0.265-1.181)	0.127
NLR-post	0.846 (0.761-0.940)	0.002	0.614 (0.389-0.969)	0.036	0.514 (0.272-0.971)	0.040

LOT=line of therapy. NLR_post=neutrophil-lymphocyte ratio after first cycle of ICIs therapy.